Madrigal Pharmaceuticals said the Maestro Nash outcomes readout is now expected in late 2027 and that it can start an even larger trial. The company reported $431 million for the third quarter and $1.1 billion in sales through Q3. The market is growing 30% this year.
MDGL · Madrigal Pharmaceuticals, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 39%
- Last earnings
- Nov 3, 2026
- Latest filing
- 10-Q · Nov 3
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Madrigal Pharmaceuticals, Inc. reported third-quarter 2026 net sales of $431.3 million, up 50% year-over-year, and its first profitable quarter, with net income of $55.4 million.
Madrigal Pharmaceuticals recorded $431.3 million in net product revenue for the three months ended September 30, 2026, versus $287.3 million in the corresponding period in 2025, and reported $55.4 million in net income.
Madrigal Pharmaceuticals reported third-quarter 2026 Rezdiffra net sales of $431.3 million, up 50% year over year, and achieved its first profitable quarter with net income of $55.4 million; year-to-date Rezdiffra net sales reached $1.1 billion.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 30, 2026TL;DR. Madrigal delivered Q2 2026 Rezdiffra net sales of $364.3 million (+71% YoY) with over 49,000 patients on therapy, added three new resmetirom patents (including an F4c patent extending protection into 2042), advanced its oral GLP-1 MGL-2086 into Phase 1, and confirmed it is comfortable with consensus quarterly growth rates for the remainder of 2026; however, operating expenses rose sharply and net loss widened to $57.9 million.
- + Rezdiffra Q2 2026 net sales grew 71% year-over-year to $364.3 million, with more than 49,000 patients on therapy (over 50,000 reached earlier in July).
- + Strengthened IP estate with three new resmetirom patents, including an F4c use patent extending protection into 2042.
- + MGL-2086 oral GLP-1 advanced into the clinic with Phase 1 single ascending dose dosing initiated in June 2026, supporting Rezdiffra combination strategy.
- + Management is comfortable with consensus quarterly net sales growth rates for Q3 and Q4 2026.
- + Trailing 12-month Rezdiffra net sales reached nearly $1.3 billion, reinforcing mega-blockbuster potential, with the addressable F2-F3 specialist market growing ~50% in two years to 460,000 patients.
- − Cost of sales surged to $40.0 million from $9.1 million, driven by higher Roche royalties and a work-in-process inventory write-down.
- − R&D expenses nearly doubled to $91.2 million from $54.1 million, with SG&A expenses rising to $289.4 million from $196.9 million as commercial investment scaled.
- − Cash, cash equivalents, restricted cash and marketable securities declined to $838.9 million at June 30, 2026 from $988.6 million at year-end 2025.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Addressable U.S. F2-F3 MASH patients | 530,000 | through June 30, 2026 | — |
| Cash, cash equivalents, restricted cash and marketable securities | $961.8M | as of Sept. 30, 2026 | — |
| Non-cash stock-based compensation expense in operating expenses | $38.9M | Third-quarter 2026 | — |
| Rezdiffra net sales | $431.3M | third-quarter 2026 | — |
| Rezdiffra year-to-date net sales | $1.1B | year-to-date 2026 | — |
| Patients on Rezdiffra | 49,000 | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MDGL
this stock
Madrigal Pharmaceuticals, Inc.
|
$8.81B | -34.9% | +432.1% | — | 9.2% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 19
Madrigal Pharmaceuticals said the Maestro Nash outcomes readout is now expected in late 2027 and that it can start an even larger trial. The company reported $431 million for the third quarter and $1.1 billion in sales through Q3. The market is growing 30% this year.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MDGL | -11.3% | -12.7% | -16.3% | -11.9% | -34.9% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -2.7% | -3.5% | -7.1% | -3.2% | -36.1% |